Veritas Genetic participates in a groundbreaking study highlighting the importance of polygenic risk scores in the clinical management of breast cancer patients

Key Findings of the Study Key Findings of the Study The study, published in the Journal of Personalized Medicine, evaluated women with a family history of breast cancer, demonstrating that PRS significantly improves the accuracy of individual risk prediction. This is particularly relevant for women who are non-carriers of pathogenic variants in susceptibility genes. For carriers of mutations in genes likeBRCA1andBRCA2, PRS offers a complementary approach that helps refine...

MADRID, 03/10/2024 (informazione.it - comunicati stampa - salute e benessere)

The study, published in the Journal of Personalized Medicine, evaluated women with a family history of breast cancer, demonstrating that PRS significantly improves the accuracy of individual risk prediction. This is particularly relevant for women who are non-carriers of pathogenic variants in susceptibility genes. For carriers of mutations in genes like and , PRS offers a complementary approach that helps refine personalized management and prevention strategies.

According to Dr. Izquierdo, Chief Medical Officer at Veritas,

PRS has the potential to transform how cancer risk is assessed and managed in patients with a family history of the disease. Dr. Izquierdo, added

Veritas Genetic leads the implementation of advanced genomic solutions, focusing on preventive and personalized medicine. Through partnerships with top-tier academic institutions, Veritas continues to drive innovation aimed at improving health and well-being.

www.veritasint.com

https://www.mdpi.com/2975338  

View original content: https://www.prnewswire.co.uk/news-releases/veritas-genetic-participates-in-a-groundbreaking-study-highlighting-the-importance-of-polygenic-risk-scores-in-the-clinical-management-of-breast-cancer-patients-302265829.html